Skip to main content
. 2022 Sep 28;19(19):12343. doi: 10.3390/ijerph191912343

Table 3.

Characteristics of the studies included in the review.

Experimental Group Control Group
Sample Characteristics Experimental Intervention Characteristics Sample Characteristics Type
Control Intervention
Author and Year Country Design K N Ne Age
(Range or Mean ± SD)
%
Fem
Type of
CP
GMFCS Level Type Dura-
tion
(weeks)
Session/Week Minutes/Session Nc Age
(Range or Mean ± SD)
% Fem
Acar, G et al. 2016 [57] Turkey RCT 1 30 15 9.53 ± 3.04 46% Spastic hemiparesis I/II NWT + CT 6 2 15 15 9.73 ± 2.86 60 CT
Alsaif, A et al. 2015 [58] Saudi Arabia RCT 4 40 20 6–10 y NR Spastic bilateral hemiparesis III NWT 12 7 20 20 6–10 y NR NI
Atasavun-Uysal, SA et al. 2016 [59] Turkey RCT 1 24 12 9.13 ± 2.57 33% Spastic unilateral I/II NWT + CT 12 2 30 12 NR 83% CT
Avcil, E et al. 2020 [60] Turkey RCT 4 30 15 10.93 ± 4.09 46% NR I/II/III/IV NWT + LMC 8 3 60 15 11.07 ± 3.24 40 CT
Chiu, HC et al. 2014 [61] Australia RCT 3 57 30 9.4 ± 1.9 50% Spastic hemiplejic I/II/III/IV/IV NWT + CT 12 3 40 27 9.5 ± 1.9 59% CT
El-Shamy, SM et al. 2018 [62] Saudi Arabia RCT 2 40 20 9.5 ± 1.2 40% Spastic hemiplejic NR NWT + CT 12 3 40 20 9.8 ± 1.2 30% CT
Sajan, JE et al. 2017 [63] India RCT 3 18 9 10.6 ± 3.78 40% Spastic bilateral I/II/III/IV NWT + CT 3 6 45 9 12.4 ± 4.93 50% CT
Shin, JW et al. 2015 [64] South Korea RCT 1 17 8 106.8 ± 2.5 months 63% Spastic bilateral NR NWT 8 2 45 9 110.8 ± 16.1 months 33% CT
Wang, TN et al. 2021 [65] China RCT 1 18 9 102.67 ± 25.05 months 66% Spastic hemiplejic NR NWT + CT 8 2 145 9 102.78 ± 25.84 months 44% CT

Abbreviations: K, Number of comparisons; N, Number of participants in study; Ne, Number of participants in experimental group; Nc, Number of participants in control group; SD, Standard Deviation; Fem, Female; CP, Cerebral Palsy; GMFCS, Gross Motor Function Classification System; RCT, Randomized Controlled Trial; NR, Not reported; NWT, Nintendo® Wii Therapy; LMC, Leap Motion Controller; NI, No intervention; CT, Conventional Therapy.